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Abstract p16INK4a, p15INK4b, p18INK4c and p19INK4d comprise a
family of cyclin-dependent kinase inhibitors and tumor suppres-
sors. We report that the INK4 proteins share the ability to arrest
cells in G1, and interact with CDK4 or CDK6 with similar
avidity. In contrast, only p18 and particularly p19 are
phosphorylated in vivo, and each of the human INK4 proteins
shows unique expression patterns dependent on cell and tissue
type, and differentiation stage. Thus, the INK4 proteins harbor
redundant as well as non-overlapping properties, suggesting
distinct regulatory modes, and diverse roles for the individual
INK4 family members in cell cycle control, cellular differentia-
tion, and multistep oncogenesis.
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1. Introduction
The cyclin-dependent kinases (CDKs) are key regulators of
the cell cycle, and as such their activities must be tightly con-
trolled [1,2]. In mammalian cells, the CDKs are negatively
regulated by proteins of two families of CDK inhibitors
(CKIs), the INK4 and Cip/Kip families [1^4]. CKIs of the
INK4 family, p16INK4a (p16), p15INK4b (p15), p18INK4c
(p18), and p19INK4d (p19), speci¢cally bind and inhibit
CDK4 and CDK6, the partner kinases of the D-type cyclins
strongly implicated in phosphorylation of the retinoblastoma
tumor suppressor protein (pRB) and thereby in G1/S control
[3^5]. On the other hand, CKIs of the Cip/Kip family, p21,
p27, and p57, inhibit a broader spectrum of CDKs including
cyclin D/CDK4(6), cyclin E/CDK2, and cyclin A/CDK2 [1^4].
The four proteins of the INK4 family share a similar structure
dominated by several ankyrin repeats, and the corresponding
genes contain an intron which interrupts the coding sequence
at the same position, indicating that they evolved from a
common ancestor [4,6,7]. In terms of biological functions,
di¡erent CKIs appear to participate in regulation and coor-
dination of cell cycle events following mitogenic stimulation,
DNA damage, mitogen deprivation, or changes in cell^cell or
cell^matrix interactions, and they have also been implicated in
inducing terminal di¡erentiation and cellular aging or senes-
cence [3^7]. Apart from their physiological roles, the CKIs are
commonly lost or inactivated by mutations in diverse types of
cancer, and they represent established or candidate tumor
suppressors. Thus, inactivation of p16 through gene deletions,
point mutations or transcriptional silencing by promoter
methylation is among the most frequent defects contributing
to oncogenesis [4^7] and, although much less extensive, there
is also evidence for abnormalities of the other INK4 proteins
in some tumors [6^9].
Given their emerging roles in fundamental physiological as
well as pathological processes, the biochemical similarities and
evolutionary homology of the INK4 family members raise an
important question of redundancy versus non-overlapping
features of p16, p15, p18 and p19. Despite the recent e¡orts
in many laboratories, the relevant data remains scattered and
partly con£icting, and further work is needed to clarify this
complex issue. For instance, it remains a matter of debate
whether the individual INK4 proteins favor CDK6 over
CDK4 as their target [6,10,11], and while transcriptional reg-
ulation of the INK4 genes is well established, it is unclear
whether the INK4 proteins are controlled also by posttransla-
tional modi¢cations, at the level of regulation which is com-
monly employed to control abundance or function of other
cell cycle regulators including CKIs of the Cip/Kip family [4].
Di¡erential expression of the INK4 genes in di¡erent mouse
tissues has been documented by mRNA analyses [12^15], yet
analogous studies in humans are lacking, and particularly
data at the protein level, in terms of tissue or cell type specif-
icity and abundance, are virtually missing for any species. In
an attempt to address some of these open questions, we have
used a range of biochemical and immunochemical approaches
to examine the degree of redundancy within the human INK4
family of cell cycle inhibitors, and our results are presented in
this report.
2. Materials and methods
2.1. Plasmids and antibodies
Human cDNAs for p15, p16, p18 and p19 were subcloned into the
vector pXmyc for expression in mammalian cells. Monoclonal anti-
bodies DCS-118 and DCS-100 were produced upon immunization of
young female BALB/c mice with bacterially produced human His-
tagged, full-length p18, and GST-tagged full-length p19, respectively,
using established procedures [16,17]. Other antibodies were: mouse
monoclonal anti-CDK6 (DCS 130.1) [17], anti-CDK4 (DCS 31.1)
[17], anti-p21 (DCS-60) [16], anti-p15 (Ab-4, NeoMarkers), anti-p16
(DCS-50) [18], anti-p16 (Pierce), anti-p16 (Ab-2, NeoMarkers), anti-
myc-epitope (9E10, provided by G. Evan), polyclonal rabbit antisera
to CDK4 (sc601, Santa Cruz), p18 (M-168, Santa Cruz), p15 (C-20,
Santa Cruz), and secondary rabbit anti-mouse IgG-HRP (Dako) and
goat anti-rabbit IgG-HRP (Vector).
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2.2. Cell culture, transfection, and £ow cytometry
Human tumor-derived cell lines U-2-OS, Saos-2, and SK-UT-1
were cultured in Dulbecco’s modi¢ed Eagle’s medium (DMEM) sup-
plemented with 10% fetal calf serum, 2 mM glutamine, and antibiot-
ics. Human teratocarcinoma cells NT2/D1 were cultured and induced
to di¡erentiate exactly as described [9,19]. Transient transfections to
express the INK4 genes in U-2-OS cells were performed using the
previously described calcium phosphate precipitate method [18]. Pro-
teins were allowed to be expressed for 0^36 h after washing o¡ the
precipitate, and the £ow cytometry analyses of cell cycle distribution
determined as described [18].
2.3. Immunochemical and immunostaining methods
Procedures for immunoprecipitation, gel electrophoresis, and im-
munoblotting were described previously, as were the techniques for
immuno£uorescence staining of cells cultured on coverslips [9,16^20].
The human tissues were from the tissue bank of the Institute of
Cancer Biology, Copenhagen, or obtained commercially as the Check-
erboard Multi-Tissue Blocks (Dako) containing sections from a wide
spectrum of normal human tissues, formalin-¢xed, para⁄n-embedded,
and mounted on poly-L-lysine-coated slides. The sensitive immunoper-
oxidase staining using the Vectastain Elite kit (Vector) was performed
as described previously [9,16,17]. Immunoprecipitations were made as
in [17], with the antibody 9E10 coupled to protein G-Sepharose and
500 Wg protein extract. Immunoprecipitated proteins were separated
on 13% polyacrylamide gel electrophoresis (PAGE), transferred onto
nitrocellulose membranes by semidry blotting, the membranes probed
with the relevant antibodies and the signal visualized by enhanced
chemiluminescence, using either the standard or the SuperSignal
ULTRA substrate (Pierce).
2.4. Production and puri¢cation of the INK4 fusion proteins
Human p15, p16, p18 and p19 cDNAs were cloned into the pGex20
T vector and expressed in BL21 Escherichia coli and puri¢ed as GST
fusion proteins according to the manufacturer’s instructions (Pharma-
cia). The BL21 cells were transformed and the fusion proteins induced
overnight by IPTG (¢nal concentration 0.1 mM). Bacterial pellets
were collected and resuspended in ELB bu¡er (50 mM HEPES, pH
7.5, 250 mM sodium chloride, 5 mM EDTA, 0.1% NP-40, 1 mM
dithiothreitol, 2.5 Wg/ml leupeptin, 2Wg/ml aprotinin, 5Wg/ml phenyl-
methylsulfonyl £uoride), lysed by sonication and the extracts cleared
by centrifugation. The supernatant was added to GST beads and
incubated end-over-end for 30 min, at 4‡C. The beads were washed
¢ve times in ELB bu¡er and the fusion protein eluted with 50 mM
Tris^HCl (pH 8), 10 mM reduced glutathione. Eluted proteins were
dialyzed against 10 mM Tris, pH 8. The protein concentration was
determined by the Bradford protein assay (Bio-Rad) and the purity
was estimated by SDS^PAGE and Coomassie staining.
2.5. Expression of CDK4 and CDK6 in insect cells, and in vitro
competition assay
Baculoviruses expressing human CDK4 and CDK6 were ampli¢ed
in Sf9 insect cells, and the High Five Insect cells were used to produce
the protein [20]. The protein concentration in the insect cell lysates
was estimated by the Bradford assay, and the lysates used for the in
vitro competition assay [20] to measure the ability of the di¡erent
INK4 proteins to interact with CDK4 or CDK6. The assay was per-
formed in 96-well £at-bottomed microtiter plates (Nunc) coated with
40 nM GST-p16 diluted in coating bu¡er (¢nal volume 100 Wl). Un-
speci¢c sites were blocked by incubation with 5% dry powder milk for
1 h. The plates were washed, and serial dilutions of the INK4 proteins
were conducted in the microtiter plate (concentration range 0.01^
1 WM), followed by addition of the insect cell extract with either
CDK4 or CDK6 (20 Wg CDK4 extract and 50 Wg CDK6 extract
per well), in a ¢nal volume of 100 Wl. After incubation for 1 h at
37‡C, the plates were washed for 30 min, and incubated with either
anti-CDK4 or anti-CDK6 antibodies for 2 h at 37‡C, followed by
washing and incubation with secondary antibodies, to detect the
CDK bound to the p16 protein coating the plate. The assay was
developed using the TMB solution as a chromogen (Kem-Tec, Den-
mark), and the color reaction was measured at 450 nm. The bu¡ers
used in the assay were as described [21].
The GST-p16 concentration required to saturate the microtiter
plate, and the amounts of CDK4- and CDK6-containing insect cell
extracts required to saturate the GST-p16-coated plate were estimated
in preliminary titration experiments to set up the assay in a linear
range (data not shown). Each experiment was performed in triplicate,
and repeated 3^4 times with very similar results.
2.6. Phosphopeptide mapping and phosphoamino acid analysis
Plasmids of interest were transfected into 25% con£uent U-2-OS
cells and the expression allowed for 12 h after washing o¡ the pre-
cipitate. Cells were subsequently starved in phosphate-free DMEM
for 30 min and then incubated in DMEM containing 2 mCi/ml
[32P]orthophosphate (Amersham) for 4 h on a rocking table at
37‡C. Cells were washed in ice-cold phosphate-bu¡ered saline and
scraped and lysed in the extraction bu¡er. After centrifugation at
14 000Ug, the supernatant was precleared on protein G-Sepharose
beads with DNase and RNase A (20 U of each) for 30 min at 4‡C.
Immunoprecipitation was performed as described above with the
monoclonal antibody 9E10, with three additional washes. Eluted pro-
teins were separated on 13% SDS^PAGE (Hoe¡er, 20 cm length gel
system) and in vitro translated myc-tagged p19 was used as a position-
al marker. Proteins were transferred onto nitrocellulose membrane
and radioactive signal detected by autoradiography or on a phosphor-
image screen (Molecular Dynamics). Bands of interest were excised
and processed for tryptic cleavage, phosphopeptide mapping and
phosphoamino acid analyses as described [21].
3. Results and discussion
3.1. Binding of INK4 proteins to CDK4 and CDK6, and G1
arrest
The four INK4 proteins share the ability to bind to CDK4
and CDK6, and inhibit the kinase activity of the cyclin D^
CDK4(6) complexes [3^5], yet partly con£icting reports indi-
cate that some of the INK4 proteins may favor CDK6 over
CDK4 as their target, implying some functional di¡erences
among the various combinations of INK4^CDK interactions,
and thus possibly di¡erential impacts on cell cycle inhibition
[6,10^12]. Factors potentially complicating any generalizations
of such studies include the use of di¡erent antibodies speci¢c
for the individual INK4 or CDK proteins, and diverse cell
lines with a considerably higher expression of CDK6 than
CDK4, or with di¡erent levels of the (partly still elusive)
assembly factors which facilitate the complex formation be-
tween CDK4(6) and the D-type cyclins [4,22]. To eliminate
such variables, we transfected Myc-tagged p15, p16, p18 and
p19 into parallel cultures of human U-2-OS cells which ex-
press wild-type pRB, all three D-type cyclins, and comparable
levels of the CDK4 and CDK6 proteins, and examined the
INK4^CDK4(6) complexes immunoprecipitated with the
same antibody against the Myc epitope at 0, 2.5, 5, 8, 12,
16, and 24 h after removing the DNA calcium phosphate
precipitate from the culture medium. The combined immuno-
precipitation and immunoblotting experiments showed com-
parable ratios of the CDK4 and CDK6 kinases bound to each
of the four INK4 proteins during these time course experi-
ments, and a representative example of the data obtained at
5 and 16 h is shown in Fig. 1A. The same cellular model was
also used to assess the cell cycle inhibitory properties of the
ectopically expressed individual INK4 family members, and
the £ow cytometry pro¢les of the transfected cells showed a
very similar, pronounced G1 arrest in every case (Fig. 1B). On
the other hand, none of the four INK4 proteins showed any
cell cycle inhibition upon transfection into the pRB-negative
human sarcoma cell line Saos-2 (data not shown), consistent
with the concept that the cyclin D-dependent kinases are
required for cell cycle progression only in cells expressing
wild-type pRB, a key substrate of cyclin D/CDK4(6) in G1
[4,5].
To directly compare the relative binding a⁄nities of the
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individual INK4 proteins towards CDK4 and CDK6, we pro-
duced these human kinases in insect cells using the baculovi-
rus expression system, and employed an in vitro binding assay
[20] to assess the ability of puri¢ed recombinant human INK4
proteins to compete for CDK4(6) binding with solid phase-
bound p16. The speci¢city of the assay was documented in
repeated experiments in which soluble wild-type p16, but not
melanoma-associated mutant p16 (P114L) [18], e⁄ciently pre-
vented the binding of CDK4 or CDK6 to wild-type p16 im-
mobilized on the plate (see Fig. 1C for an example). The
P114L mutant p16 showed signi¢cant binding to CDK4(6)
only at the highest concentration used (1 WM), consistent
with previous data that this and other tumor-associated mis-
sense mutants of p16 are defective but not entirely devoid of
the ability to bind and inhibit the cyclin D-dependent kinases
[4,18]. Most signi¢cantly, wild-type versions of the other
members of the INK4 family were able to compete for bind-
ing to CDK4(6) in a manner indistinguishable from the wild-
type p16 used in parallel (Fig. 1C, and data not shown).
Collectively, these immunoprecipitation and binding competi-
tion data are fully consistent with the notion that the INK4
proteins bind CDK4 and CDK6 with similar a⁄nity, and that
there are no major di¡erences among the INK4 family mem-
bers in their avidity towards the CDK4(6) partners, or the
ability to impose a G1 arrest in RB-positive cells.
3.2. Di¡erential phosphorylation of INK4 proteins in vivo
Phosphorylation and dephosphorylation events regulate
function, subcellular localization, and turnover of diverse
cell cycle regulatory proteins including the CDK inhibitors
of the Cip/Kip family [1^4]. On the other hand, there have
been no reports of phosphorylation of any of the INK4 pro-
teins, despite intensive characterization of at least the most
studied member, the p16 tumor suppressor [6,7]. To see
whether any of the INK4 proteins is phosphorylated in hu-
man cells, wild-type p15, p16, p18 and p19 were transiently
expressed to similar levels in exponentially growing U-2-OS
cells, the cells were labeled with radioactive orthophosphate,
and the immunoprecipitated INK4 proteins examined by gel
electrophoresis and autoradiography and/or phosphorimage
analysis. Unexpectedly, there was a clear distinction among
the members of the family with respect to their phosphory-
Fig. 1. Binding to CDK4 and CDK6, and induction of G1 arrest
by human INK4 proteins. A: Myc-tagged p15, p16, p18, and p19
were ectopically expressed in U-2-OS cells, the INK4 proteins im-
munoprecipitated from cell extracts at indicated time points after re-
moval of calcium phosphate precipitate via the 9E10 antibody to
myc, and the complexes analyzed by immunoblotting for the pres-
ence of CDK4 and CDK6 (using a mix of DCS-31 and DCS-130
antibodies) and the tagged INK4 proteins (using 9E10); v = empty
vector control; WCL = whole cell lysate of untransfected cells. B: A
graph of a typical £ow cytometry evaluation of the cell cycle e¡ects
of the myc-tagged INK4 proteins ectopically expressed in exponen-
tially growing U-2-OS cells, compared to cells transfected with
empty vector (v). C: Example of the plate binding assay, with in-
creasing concentrations of soluble GST-p16, -p18, and -p19 compet-
ing for CDK6 with the plate-immobilized GST-p16.
Fig. 2. Two-dimensional phosphopeptide maps of human p19 and
p18 phosphorylated in vivo. X indicates the sample application
spot; a^d: the four di¡erent phosphorylated peptides reproducibly
found in tryptic digests of p19; e: the only tryptic phosphopeptide
detected in p18.
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lation. Whereas no 32P labeling of p15 or p16 was found in
repeated experiments, there was detectable phosphorylation in
p18, and an even stronger signal in p19. Phosphoamino acid
analysis of the proteins labeled in vivo revealed the presence
of phosphoserine in p18, while p19 was phosphorylated on
both serine and threonine residues. As can be seen from the
representative examples of two-dimensional phosphopeptide
maps (Fig. 2), tryptic digestion of p19 reproducibly resulted
in four labeled spots termed here a^d, in contrast to p18
which appears to be labeled in only one peptide (Fig. 2).
These experiments identi¢ed a previously unrecognized post-
translational modi¢cation of a subset of the INK4 family
members, and we are currently attempting to map the phos-
phorylation sites as a prerequisite for elucidating the biolog-
ical signi¢cance of this phenomenon. Our initial cycle se-
quencing and site-directed mutagenesis experiments have so
far identi¢ed serines 66 and 76 of human p19 as the residues
phosphorylated in spots b and c (Fig. 2). Whereas spot b
represents a peptide phosphorylated on both Ser 66 and 76,
spot c corresponds to the same tryptic peptide but phosphor-
ylated on Ser 76 only. The serines 66 and 76 are located on
the surface of p19 as judged from its three-dimensional struc-
ture [23], and they are conserved in mouse p19, but not in the
other three human INK4 proteins [6]. These results suggest
why the cellular kinases which target p19 are unable to mod-
ify the other, closely related INK4 proteins, and the occur-
rence and complexity of phosphorylation separates p19 from
the rest of the family. Such a speci¢c series of phosphorylation
events on phylogenetically conserved residues points to a can-
didate novel mechanism to control some aspect(s) of p19 func-
tion, a feature unique in the INK4 family, or at least distinct
from p15 and p16.
3.3. Expression patterns of the INK4 proteins in human tissues
One feature that distinguishes the individual INK4 genes
appears to be their distinct transcriptional control, in that
their promoters respond di¡erentially to diverse stimuli. In-
duction of p15 in response to transforming growth factor L,
or upregulation of p16 with increasing population doublings
or following some oncogenic stimuli are among examples of
such di¡erential transcriptional regulation (reviewed in [6,7]).
Apart from studies with cultured cellular models, data from
analyses of tissues in situ, so far largely limited to some mouse
tissues and stages of development, suggest that the individual
INK4 genes may be expressed in a stage- or cell type-re-
stricted manner [12^15,24,25]. To test this attractive hypoth-
esis in the human system where no comparative analysis of the
INK4 proteins is presently available, we examined abundance
and tissue type speci¢city of p16, p15, p18 and p19 immuno-
histochemically on a wide spectrum of human tissues using
para⁄n-embedded multi-tissue arrays. Interpretation of the
immunostaining patterns by an experienced histopathologist
allowed us to draw the following conclusions. In adult human
tissues, the INK4 protein most widely expressed was p18,
Fig. 3. Immunohistochemical detection of endogenous p18 and p16
in normal human skin. A: Immunoperoxidase staining with anti-
body against p16 (Pierce) is mainly restricted to some keratinocytes
of the ¢rst suprabasal layer, and only rare stromal elements.
B: Staining with antibody DCS-118 shows predominantly nuclear
positivity of p18 in the majority of epidermal keratinocytes includ-
ing several suprabasal layers, and numerous stromal cells. Magni¢-
cation U200.
Fig. 4. Immunoblots of human NT2/D1 cells during retinoid acid-
induced di¡erentiation. Time 0 represents exponentially growing
cells; TD are the enriched neuron-like ‘terminally di¡erentiated’ cells
42 days after induction. Control cell lines (C) included U-2-OS for
cyclin B1, p21, SK-UT-1 for p15, p16, p18, p19, and CDK7 (a sta-
ble protein used as a loading control). Blots probed with the indi-
cated antibodies were developed using the standard chemilumines-
cence method, except for p15, p18, and p19 for which the
SuperSignal ULTRA substrate (Pierce) was used to enhance the sig-
nal.
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followed by p15, p16, and p19 being the most restricted one.
Thus, p18 was clearly detectable in all tissues examined, in-
cluding diverse muscle, lymphoid, epithelial, neural and endo-
crine tissues, endothelium, and stromal cells, while p19 was
largely negative, with only restricted cell types such as occa-
sional lymphoid and rare glandular epithelial cells, seminifer-
ous tubules, and adrenal gland cells showing detectable p19
protein. Unlike p18 which was expressed in an almost homo-
geneous pattern in many tissues, the staining signals for p15
and p16 were very variable from cell to cell, with the excep-
tion of endothelium and some simple (glandular) epithelia
which were virtually homogeneously positive for p15. An ex-
ample of the di¡erential staining patterns is shown for p16
and p18 in the epidermis, with p18 clearly more widely ex-
pressed in both the strati¢ed squamous epithelium and the
stroma (Fig. 3A,B). Compared to available data on expression
of the INK4 genes in mice, our results suggest a considerably
narrower spectrum of tissues with detectable p19, and a sig-
ni¢cantly wider range of tissues with detectable p16 protein
([12^15,24^26], and this study). Whether inter-species and/or
age-related di¡erences [6,12^15,24], or possibly posttranscrip-
tional control mechanisms a¡ecting the protein but not
mRNA levels, can explain such signi¢cantly di¡erent ¢ndings
remains to be established. Apart from the unexpectedly re-
stricted expression of p19, it appeared that most human tis-
sues express concomitantly two or more members of the
INK4 family, possibly providing overlapping functions critical
for tissue homeostasis. The concept of at least partly redun-
dant roles in many cell types is also consistent with the limited
phenotypes of gene knock-out mice selectively deprived of
only one member of the INK4 family [26^29].
3.4. Dynamic expression patterns of the INK4 proteins in
di¡erentiating teratocarcinoma cells
The CKIs of the Kip/Cip family have been widely impli-
cated in the switch between proliferation and di¡erentiation
[1^4], and recent limited evidence from in situ hybridization of
mouse neural tissues [14], and in vitro di¡erentiation models
of muscle [12,15] and hematopoietic cells [25] indicate that the
INK4 proteins may also contribute to commitment or main-
tenance of di¡erentiation, at least in some lineages. Our im-
munohistochemical analysis showed widespread expression of
p18, and detection of some of the INK4 proteins in non-pro-
liferating, terminally di¡erentiated cells and tissues. These re-
sults appeared consistent with the potential involvement of the
INK4 proteins in di¡erentiation, including for instance the
staining of p18 and p15 in adult human muscle, neural gan-
glia, and some di¡erentiated epithelial tissues. To further elu-
cidate the emerging relationship between expression of the
INK4 inhibitors and cell di¡erentiation in a dynamic model
system, we explored the commonly used human teratocarci-
noma cell line NT2/D1 [9,19], which can be induced to di¡er-
entiate along the neuronal lineage. Following the established
protocols [19], we exposed exponentially growing NT2/D1
cells to retinoic acid and followed their gradual cessation of
proliferation, and the eventual emergence of di¡erentiated,
quiescent neuronal cells with extended neurites and formation
of ganglion-like structures ([9,19], and data not shown). A
decisive proliferative change became apparent towards the
end of the second week of the induction period, accompanied
by disappearance of cyclin B1, induction of Cip/Kip inhibitors
such as p21, and the lack of DNA replication (Fig. 4 and data
not shown). Time course immunoblotting analyses of the four
INK4 proteins showed reproducible, dynamic patterns char-
acteristic for each family member. Thus, the abundance of p18
remained relatively high and virtually constant throughout the
6-week di¡erentiation period, while p15 was lacking in the
exponentially growing cells and became induced very early
(at day 1^2 of retinoic acid treatment), and the p15 protein
acquired a characteristic double band appearance in the third
week of induction (Fig. 4). Unexpectedly, p19 was transiently
elevated between days 10 and 18 of the treatment, while p16
remained undetectable for several weeks, and only became
induced in the ¢nal stages of the experiment, some 3 weeks
after the cells became quiescent (Fig. 4). These surprisingly
dynamic and complex patterns of the INK4 proteins suggest
potential involvement of at least p15 and p19 in the gradual
transition from proliferating to quiescent, di¡erentiated cells,
and possibly some role of p16 in the terminal di¡erentiation in
the NT2/D1 model system. Considered from a more general
perspective, these results emphasize the critical impact of the
fourth dimension of all biological systems, namely the time-
dependent, dynamic patterns of the INK4 proteins during
development and tissue renewal. Indeed, the time-dependent
expression/accumulation might also account for the puzzling
loss of p16 in many human tumors [4^7], in contrast to only
rare examples of cancer-associated aberrations of the other,
structurally similar INK4 inhibitors [4^9]. Thus, the p16
mRNA and protein gradually accumulate with increasing
cell age [6,7], and increase more acutely in response to
DNA damage or some oncogenic stimuli [6,7,30], and it
may be these timely safeguard responses which distinguish
p16 as a guardian of cellular proliferation, and a prominent
tumor suppressor.
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